Literature DB >> 6519775

Inhibition of human neutrophil secondary granule discharge by antiinflammatory agents.

J Davies, K Sheppard, J Fletcher.   

Abstract

Human neutrophil cobalamin binding protein (NCBP) is located exclusively in the neutrophil secondary granules. The soluble stimuli formlymethionyl-leucyl-phenylalanine and the low-molecular-weight complement fragment C5a both promote the dose-dependent release of NCBP from cytochalasin B-treated neutrophils in vitro. The extracellular discharge of NCBP induced by higher secretagogue is inhibited by prior exposure of neutrophils to the corticosteroids hydrocortisone and methylprednisolone and the nonsteroidal antiinflammatory agents indomethacin and ibuprofen. The four antiinflammatory agents function as competitive antagonists of neutrophil secondary granule discharge with a site of action at or near the cell surface. These findings support the hypothesis that antiinflammatory agents prevent neutrophil activation in vitro by inhibition of stimulus-receptor coupling. The significance of these observations with regard to the in vivo actions of these agents remains uncertain, however.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519775     DOI: 10.1007/bf00918211

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  21 in total

1.  MEASUREMENT OF SERUM VITAMIN B12 LEVEL USING RADIOISOTOPE DILUTION AND COATED CHARCOAL.

Authors:  K S LAU; C GOTTLIEB; L R WASSERMAN; V HERBERT
Journal:  Blood       Date:  1965-08       Impact factor: 22.113

Review 2.  Activation, activities and pharmacologically active products of complement.

Authors:  W Vogt
Journal:  Pharmacol Rev       Date:  1974-06       Impact factor: 25.468

3.  Effect of intravascular complement activation on granulocyte adhesiveness and distribution.

Authors:  J T O'Flaherty; P R Craddock; H S Jacob
Journal:  Blood       Date:  1978-04       Impact factor: 22.113

4.  Drugs which inhibit prostaglandin biosynthesis.

Authors:  R J Flower
Journal:  Pharmacol Rev       Date:  1974-03       Impact factor: 25.468

5.  The role of activated complement and granulocytes in shock states and myocardial infarction.

Authors:  H S Jacob
Journal:  J Lab Clin Med       Date:  1981-11

6.  Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist.

Authors:  C Dahinden; J Fehr
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

7.  Synergy among agents inhibiting granulocyte aggregation.

Authors:  D E Hammerschmidt; P J Flynn; P A Coppo; K M Skubitz; H S Jacob
Journal:  Inflammation       Date:  1982-06       Impact factor: 4.092

8.  Production of acute pulmonary injury by leukocytes and activated complement.

Authors:  D C Hohn; A J Meyers; S T Gherini; A Beckmann; R E Markison; A M Churg
Journal:  Surgery       Date:  1980-07       Impact factor: 3.982

9.  Lactoferrin: a promoter of polymorphonuclear leukocyte adhesiveness.

Authors:  R Oseas; H H Yang; R L Baehner; L A Boxer
Journal:  Blood       Date:  1981-05       Impact factor: 22.113

10.  Role of arachidonic acid derivatives in neutrophil aggregation: a hypothesis.

Authors:  J T O'Flaherty; H J Showell; E L Becker; P A Ward
Journal:  Prostaglandins       Date:  1979-06
View more
  4 in total

1.  'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment.

Authors:  A D Dwarakanath; J Nash; J M Rhodes
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

2.  Alterations in neutrophil superoxide production following piroxicam therapy in patients with rheumatoid arthritis.

Authors:  D E Van Epps; S Greiwe; J Potter; J Goodwin
Journal:  Inflammation       Date:  1987-03       Impact factor: 4.092

3.  Inhibition of neutrophil superoxide production by fanetizole.

Authors:  B Styrt; R E Rocklin; M S Klempner
Journal:  Inflammation       Date:  1985-09       Impact factor: 4.092

4.  The origin of plasma neutrophil gelatinase-associated lipocalin in cardiac surgery.

Authors:  Arie Passov; Liisa Petäjä; Marjut Pihlajoki; Ulla-Stina Salminen; Raili Suojaranta; Antti Vento; Sture Andersson; Ville Pettilä; Alexey Schramko; Eero Pesonen
Journal:  BMC Nephrol       Date:  2019-05-22       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.